- Home
- PEBK vs DTIL Comparison
PEBK vs DTIL Comparison
Compare PEBK & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | DTIL |
|---|---|---|
| Founded | 1912 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.2M | 197.9M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PEBK | DTIL |
|---|---|---|
| Price | $42.92 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 16.2K | ★ 231.8K |
| Earning Date | 04-20-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | ★ 21.48 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.33 | $3.53 |
| 52 Week High | $45.78 | $9.62 |
Technical Indicators
Market Signals| Indicator | PEBK | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 32.85 |
| Support Level | $42.76 | $6.02 |
| Resistance Level | $43.48 | $7.92 |
| Average True Range (ATR) | 0.88 | 0.40 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 20.61 | 8.72 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).